Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
30 avr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
Two patients have been implanted in the final cohort of the trial Final cohort is actively enrolling adult patients undergoing vitrectomy FORT WORTH, Texas, April 30, 2024 (GLOBE NEWSWIRE) --...
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
16 avr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA
12 mars 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
REYKJAVIK, Iceland and FORT WORTH, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a...
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
14 févr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
11 juil. 2023 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter...
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
31 mai 2023 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley
08 nov. 2022 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other...
Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001
13 sept. 2022 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas and REYKJAVIK, Iceland, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa,...
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund
15 juin 2022 07h30 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
Nacuity Pharmaceuticals Appoints Robert R. Ruffolo, Ph.D., to Board of Directors
24 août 2021 07h30 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular...